Pfizer’s Obesity Pipeline Poised to Challenge Novo Nordisk
Pfizer is quietly building a GLP-1 obesity pipeline that could alter the competitive landscape, while investors seek ...
Target date funds adjust asset allocations over time toward a chosen retirement year, simplifying diversification and rebalancing for many savers.
19,808 articlesPfizer is quietly building a GLP-1 obesity pipeline that could alter the competitive landscape, while investors seek ...
Trump calls on Congress to codify a permanent 15% ethanol blend in gasoline, a move aimed at easing prices and streng...
ServiceNow has built a durable software platform with strong margins and steady growth. This article explains why the...
Teradyne spiked after Micron's strong results suggested AI-driven demand for memory and processing chips remains inta...
A top economist contends inflation is nearing a turning point, with a single gauge guiding bond yields and mortgage c...
A clear, actionable look at beyond (xair) 2026 earnings and what a Q4 earnings call could reveal. Learn how to read t...
Crypto markets have punished many altcoins this year, but opportunity can emerge from disciplined analysis. This guid...
Comcast plans to divide into two publicly traded entities, creating separate growth stories for NBCUniversal and the ...
Memory prices and AI data demands have put Micron and Sandisk in the spotlight. This piece breaks down what’s driving...
Marvell Technology extended a dramatic rally, up 45% in a month on record revenue, while investors weigh whether to t...
Cardano ADA is trading within a tight range as traders weigh the ghost chain label and upcoming ecosystem development...
In 2026, one AI-focused stock has become the darling of bulls and analysts alike. This article dives into the reasons...